• Live All the last hour on the coronavirus

An experimental monoclonal antibody treatment against Covid-19 being developed by Eli Lilly and AbCellera Biologics can "potently" neutralize numerous variants of the

coronavirus

, including those first identified in the United Kingdom, Brazil, South Africa, California and New York, according to scientists have discovered in experiments with test tubes.

The antibody - known as LY-CoV1404 or LY3853113 - works by attaching itself to a site in the virus that has shown few signs of mutation, meaning

the drug

is

likely to remain effective over time

, researchers say in a report. posted Friday in

bioRxiv

ahead of peer review.

"New variant-resistant treatments, such as LY-CoV1404, are desperately needed, as some of the existing therapeutic antibodies are less effective or ineffective against certain variants and

the impact of variants

on the efficacy of the

drug is still

not well understood.

vaccine, "wrote the research team.

A spokesman for AbCellera said the company plans to release information on human trials of the drug on Tuesday.

(https://bit.ly/3gYQnAU)

These are the preliminary conclusions of one of the latest scientific studies on the new

coronavirus

and efforts to find treatments and vaccines for Covid-19, the disease caused by the virus.

Antibodies, detectable at 12 months

Some Covid-19 survivors infected early in the

coronavirus

pandemic

still have

detectable antibodies to the virus a year later

, according to another new study on the disease that has caused a pandemic.

American doctors collected blood samples from 250 patients, including 58 who had been hospitalized for Covid-19 and 192 who had not required hospitalization.

Six to 10 months after diagnosis, all former inpatients and 95% of outpatients continued to have

neutralizing antibodies

, according to a report published Sunday in

medRxiv

prior to peer review.

In the small subgroup of those who were followed for a full year, 8 of 8 people who had been hospitalized continued to have antibodies, as did 9 of 11 former outpatients.

Antibody levels at the time of follow-up

were correlated with age and severity

of Covid-19 disease.

The researchers reported that older age was associated with higher levels of neutralizing antibodies, while the levels were "lower and more variable" in participants younger than 65 who experienced less severe Covid-19 and did not require hospitalization.

They said vaccinating Covid-19 survivors "would be prudent" because vaccine-induced protection against the virus will likely be more durable than antibodies induced by mild COVID-19.

According to the criteria of The Trust Project

Know more

  • Coronavirus

  • Covid 19

PoliticsPablo Casado censures the Government for "interrupting the vaccination campaign" of AstraZeneca

Brussels sues AstraZeneca for breaching the contract on its coronavirus vaccines

Interview "With scheduled vaccine deliveries we should be able to vaccinate 70% of our adult population by late summer"

See links of interest

  • Work calendar

  • Elections

  • Madrid Election Result

  • Coronavirus

  • Home THE WORLD TODAY

  • Sabadell - Rayo Vallecano

  • West Bromwich Albion - Wolverhampton Wanderers

  • Torino - Parma

  • Seville - Athletic Club

  • Albacete - Alcorcón